TTC-352 is an orally bioavailable selective human estrogen receptor (ER) alpha partial agonist (ShERPA). TTC-352 inhibits the growth of three ER+ breast cancer cells. TTC-352 induces tumor regression accompanied by exit of ERalpha from the nucleus to extranuclear sites[1][2].
Molecular Weight:
352.38
CAS Number:
[1607819-68-0]
Formula:
C20H13FO3S
Target:
Estrogen Receptor/ERR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
